Wiedenroth Christoph B, Steinhaus Kristin, Rolf Andreas, Breithecker Andreas, Adameit Miriam S D, Kriechbaum Steffen D, Haas Moritz, Roller Fritz, Hamm Christian W, Ghofrani H-Ardeschir, Mayer Eckhard, Guth Stefan, Liebetrau Christoph
Kerckhoff Heart and Thorax Center, Department of Thoracic Surgery, Bad Nauheim, Germany.
University of Göttingen, Department of Cardiology and Pneumology, Göttingen, Germany.
Thorac Cardiovasc Surg. 2025 Apr;73(3):237-243. doi: 10.1055/s-0043-1772770. Epub 2023 Aug 29.
Balloon pulmonary angioplasty (BPA) is a promising interventional treatment for inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Evidence in favor of BPA is growing, but long-term data remain scarce. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) is validated for the assessment of patients with pulmonary hypertension within three domains: symptoms, activity, and quality of life (QoL). The aim of the present study was to evaluate the long-term effects of BPA on these domains in patients with inoperable CTEPH.
Between March 2014 and August 2019, technically inoperable patients with target lesions for BPA were included in this prospective, observational study. CAMPHOR scores were compared between baseline (before the first BPA) and 6 months after the last intervention and also for scores assessed at annual follow-ups.
A total of 152 patients had completed a full series of BPA interventions and a 28 (interquartile range [IQR]: 26-32) week follow-up. Further follow-up assessments including the CAMPHOR score were performed 96 (IQR: 70-117) weeks, 178 (IQR: 156-200) weeks, and 250 (IQR: 237-275) weeks after the last intervention. From baseline to the last follow-up, CAMPHOR scores for symptoms, activity, and QoL improved from 9 (IQR: 6-14) to 3 (IQR: 0-9) ( < 0.001), 8 (IQR: 5-12) to 4 (IQR: 2-8) ( < 0.001), and 5 (IQR: 2-9) to 1 (IQR: 0-5) ( < 0.001).
BPA leads to long-lasting, significant improvement of symptoms, physical capacity, and QoL in inoperable CTEPH patients.
球囊肺动脉血管成形术（BPA）是一种针对无法手术的慢性血栓栓塞性肺动脉高压（CTEPH）的有前景的介入治疗方法。支持BPA的证据越来越多，但长期数据仍然稀缺。剑桥肺动脉高压结局评估（CAMPHOR）已被验证可用于在三个领域评估肺动脉高压患者：症状、活动能力和生活质量（QoL）。本研究的目的是评估BPA对无法手术的CTEPH患者这些领域的长期影响。
在2014年3月至2019年8月期间，将技术上无法手术且有BPA靶病变的患者纳入这项前瞻性观察性研究。比较基线（首次BPA前）和最后一次干预后6个月的CAMPHOR评分，以及年度随访时评估的评分。
共有152例患者完成了一系列完整的BPA干预和28（四分位间距[IQR]：26 - 32）周的随访。在最后一次干预后96（IQR：70 - 117）周、178（IQR：156 - 200）周和250（IQR：237 - 275）周进行了包括CAMPHOR评分在内的进一步随访评估。从基线到最后一次随访，症状、活动能力和QoL的CAMPHOR评分分别从9（IQR：6 - 14）改善到3（IQR：0 - 9）（<0.001）、从8（IQR：5 - 12）改善到4（IQR：2 - 8）（<0.001）、从5（IQR：2 - 9）改善到1（IQR：0 - 5）（<0.001）。
BPA可使无法手术的CTEPH患者的症状、身体能力和QoL得到持久、显著的改善。
